PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination

European Journal of Radiology

Volumn 73, Issue 3, 2010, Pages 470-480

  Czernin, Johannes ^a   Benz, Matthias R ^a   Allen Auerbach, Martin S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; FDG; PET CT; Warburg effect

Indexed keywords

BREAST CANCER; CANCER CELLS; CANCER PATIENTS; COLORECTAL CANCER; CT IMAGING; CT SCAN; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; HEAD-AND-NECK CANCER; IMAGING PROTOCOL; LUNG CANCER; LUNG NODULE; METABOLIC PHENOTYPE; PATIENT MANAGEMENT; PET/CT SCANNERS; STATE OF THE ART; THERAPEUTIC MONITORING; WHOLE BODY; WHOLE-BODY IMAGING;

BIOLOGICAL ORGANS; GLUCOSE; ONCOLOGY;

TUMORS;

FLUORODEOXYGLUCOSE F 18; GLUCOSE;

BREAST CANCER; CANCER SCINTISCANNING; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; GLUCOSE METABOLISM; GLYCOLYSIS; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG NODULE; LYMPH NODE METASTASIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; PATIENT MONITORING; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; WHOLE BODY SCINTISCANNING;

CONTRAST MEDIA; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLYCOLYSIS; HUMANS; NEOPLASM STAGING; NEOPLASMS; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 77949539924     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2009.12.023     Document Type: Review

References (95)

1. Warburg O., Posener K., and Negelein E. The metabolism of cancer cells. Biochem Zeitschr 152 (1924) 129-169
2. Gallagher B.M., Fowler J.S., Gutterson N.I., MacGregor R.R., Wan C.N., and Wolf A.P. Metabolic trapping as a principle of oradiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-d-glucose. J Nucl Med 19 October (10) (1978) 1154-1161
3. Som P., Atkins H.L., Bandoypadhyay D., et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-d-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 21 July (7) (1980) 670-675
4. Phelps M.E., Hoffman E.J., Mullani N.A., and Ter-Pogossian M.M. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 16 March (3) (1975) 210-224
5. Dahlbom M., Hoffman E.J., Hoh C.K., et al. Whole-body positron emission tomography: part I. Methods and performance characteristics. J Nucl Med 33 June (6) (1992) 1191-1199
6. Beyer T., Townsend D.W., Brun T., et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 41 August (8) (2000) 1369-1379
7. Townsend D.W., and Cherry S.R. Combining anatomy and function: the path to true image fusion. Eur Radiol 11 10 (2001) 1968-1974
8. Kinahan P.E., Townsend D.W., Beyer T., and Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys 25 October (10) (1998) 2046-2053
9. Czernin J., Allen-Auerbach M., and Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 48 January (1 Suppl.) (2007) 78S-88
10. Gatenby R.A., and Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat Rev 4 November (11) (2004) 891-899
11. Phelps M.E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA 97 August (16) (2000) 9226-9233
12. Vander Heiden M.G., Plas D.R., Rathmell J.C., Fox C.J., Harris M.H., and Thompson C.B. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol 21 September (17) (2001) 5899-5912
13. Majumder P.K., Febbo P.G., Bikoff R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10 June (6) (2004) 594-601
14. Kunkel M., Reichert T.E., Benz P., et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97 February (4) (2003) 1015-1024
15. Allen-Auerbach M., Yeom K., Park J., Phelps M., and Czernin J. Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer. J Nucl Med 47 February (2) (2006) 298-301
16. Goerres G.W., Burger C., Schwitter M.R., Heidelberg T.N., Seifert B., and von Schulthess G.K. PET/CT of the abdomen: optimizing the patient breathing pattern. Eur Radiol 13 April (4) (2003) 734-739
17. Cohade C., Osman M., Leal J., and Wahl R.L. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 44 November (11) (2003) 1797-1803
18. Heusner T.A., Kuehl H., Veit-Haibach P., et al. Highly iodinated intravenous contrast material for PET/CT-a feasibility study. Rofo 180 August (8) (2008) 740-745
19. Halpern B.S., Dahlbom M., Auerbach M.A., et al. Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study. J Nucl Med 46 April (4) (2005) 603-607
20. Halpern B.S., Dahlbom M., Quon A., et al. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med 45 May (5) (2004) 797-801
21. Benz M.R., Czernin J., Allen-Auerbach M.S., et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res April (15) 8 (2009) 2856-2863
22. Benz M.R., Evilevitch V., Allen-Auerbach M.S., et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med 49 July (7) (2008) 1038-1046
23. Evilevitch V., Weber W.A., Tap W.D., et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 14 February (3) (2008) 715-720
24. Benz MR, Czernin J, Dry SM, et al. Quantitative FDG-PET accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer, 2009 Nov 18. [Epub ahead of print].
25. Eilber F.C., Rosen G., Eckardt J., et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 19 July (13) (2001) 3203-3209
26. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. New Engl J Med 348 June (25) (2003) 2500-2507
27. Veit-Haibach P., Antoch G., Beyer T., et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol 80 July (955) (2007) 508-515
28. Ratib O. PET/CT image navigation and communication. J Nucl Med 45 January (90010) (2004) 46S-55
29. Cohade C., Mourtzikos K.A., and Wahl R.L. "USA-Fat": prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET/CT. J Nucl Med 44 August (8) (2003) 1267-1270
30. Syed R., Bomanji J.B., Nagabhushan N., et al. Impact of combined (18)F-FDG PET/CT in head and neck tumours. Br J Cancer 92 March (6) (2005) 1046-1050
31. Zimmer L.A., Snyderman C., Fukui M.B., et al. The use of combined PET/CT for localizing recurrent head and neck cancer: the Pittsburgh experience. Ear, Nose, Throat J 84 February (2) (2005) 104 106, 108-110
32. Branstetter IV B.F., Blodgett T.M., Zimmer L.A., et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone?. Radiology 235 May (2) (2005) 580-586
33. Schoder H., Yeung H.W.D., Gonen M., Kraus D., and Larson S.M. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 231 April (1) (2004) 65-72
34. Gordin A., Daitzchman M., Doweck I., et al. Fluorodeoxyglucose-positron emission tomography/computed tomography imaging in patients with carcinoma of the larynx: diagnostic accuracy and impact on clinical management. Laryngoscope 116 February (2) (2006) 273-278
35. Schoder H., Carlson D.L., Kraus D.H., et al. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 47 May (5) (2006) 755-762
36. Comoretto M., Balestreri L., Borsatti E., Cimitan M., Franchin G., and Lise M. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT. Radiology 249 October (1) (2008) 203-211
37. Judenhofer M.S., Wehrl H.F., Newport D.F., et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 14 4 (2008) 459-465
38. Schoder H., Fury M., Lee N., and Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 50 May (Suppl. 1) (2009) 74S-88
39. Kao J., Vu H.L., Genden E.M., et al. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer June (2009)
40. Moeller B.J., Rana V., Cannon B.A., et al. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol 27 May (15) (2009) 2509-2515
41. Gould M.K., Maclean C.C., Kuschner W.G., Rydzak C.E., and Owens D.K. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285 February (7) (2001) 914-924
42. Yi C.A., Lee K.S., Kim B.-T., et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 47 March (3) (2006) 443-450
43. Kim S.K., Allen-Auerbach M., Goldin J., et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med 48 February (2) (2007) 214-220
44. McKenna Jr. R.J., Libshitz H.I., Mountain C.E., and McMurtrey M.J. Roentgenographic evaluation of mediastinal nodes for preoperative assessment in lung cancer. Chest 88 August (2) (1985) 206-210
45. Dwamena B.A., Sonnad S.S., Angobaldo J.O., and Wahl R.L. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 213 November (2) (1999) 530-536
46. Antoch G., Stattaus J., Nemat A.T., et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229 November (2) (2003) 526-533
47. Halpern B.S., Schiepers C., Weber W.A., et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 128 4 (2005) 2289-2297
48. Keidar Z., Haim N., Guralnik L., et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 45 October (10) (2004) 1640-1646
49. De Leyn P., Stroobants S., De Wever W., et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: a Leuven lung cancer group study. J Clin Oncol 24 July (21) (2006) 3333-3339
50. Cerfolio R.J., Bryant A.S., and Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 131 6 (2006) 1229-1235
51. Fischer B., Lassen U., Mortensen J., et al. Preoperative staging of lung cancer with combined PET-CT. New Engl J Med 361 July (1) (2009) 32-39
52. van Tinteren H., Hoekstra O.S., Smit E.F., et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359 9315 (2002) 1388-1393
53. Verboom P., Tinteren H., Hoekstra O., et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 30 11 (2003) 1444-1449
54. Kong F-MS, Frey K.A., Quint L.E., et al. A pilot study of [18F]Fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 25 July (21) (2007) 3116-3123
55. Fueger B.J., Weber W.A., Quon A., et al. Performance of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 7 September-October (5) (2005) 369-376
56. Tatsumi M., Cohade C., Mourtzikos K.A., Fishman E.K., and Wahl R.L. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 33 March (3) (2006) 254-262
57. Dirisamer A., Halpern B.S., Flory D., et al. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol January (2009)
58. Heusner T.A., Kuemmel S., Hahn S., et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging May (2009)
59. Cook G., Houston S., Rubens R., Maisey M., and Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16 October (10) (1998) 3375-3379
60. Du Y., Cullum I., Illidge T.M., and Ell P.J. Fusion of metabolic function and morphology: sequential [18F]Fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 25 August (23) (2007) 3440-3447
61. Avril N., Sassen S., and Roylance R. Response to therapy in breast cancer. J Nucl Med 50 May (Suppl. 1) (2009) 55S-63
62. Delbeke D., Vitola J.V., Sandler M.P., et al. Staging recurrent metastatic colorectal carcinoma with pet. J Nucl Med 38 August (8) (1997) 1196-1201
63. Schiepers C., Penninckx F., De Vadder N., et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 21 October (5) (1995) 517-522
64. Kamel I.R., Cohade C., Neyman E., Fishman E.K., and Wahl R.L. Incremental value of CT in PET/CT of patients with colorectal carcinoma. Abdom Imaging 29 November-December (6) (2004) 663-668
65. Kim J.H., Czernin J., Allen-Auerbach M.S., et al. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 46 April (4) (2005) 587-595
66. Votrubova J., Belohlavek O., Jaruskova M., et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 33 July (7) (2006) 779-784
67. Even-Sapir E., Parag Y., Lerman H., et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 232 September (3) (2004) 815-822
68. Selzner M., Hany T.F., Wildbrett P., McCormack L., Kadry Z., and Clavien P.A. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?. Ann Surg 240 6 (2004) 1027-1034 discussion 1035-1026
69. Capirci C., Rampin L., Erba P.A., et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 34 October (10) (2007) 1583-1593
70. Melton G.B., Lavely W.C., Jacene H.A., et al. Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg 11 August (8) (2007) 961-969 discussion 969
71. Allen-Auerbach M., Quon A., Weber W.A., et al. Comparison between 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 6 November-December (6) (2004) 411-416
72. Freudenberg L.S., Antoch G., Schutt P., et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 31 March (3) (2004) 325-329
73. Schaefer N.G., Hany T.F., Taverna C., et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT?. Radiology 232 September (3) (2004) 823-829
74. Tatsumi M., Cohade C., Nakamoto Y., Fishman E.K., and Wahl R.L. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 237 December (3) (2005) 1038-1045
75. Hutchings M., Loft A., Hansen M., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 January (1) (2006) 52-59
76. Kobe C., Dietlein M., Franklin J., et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112 November (10) (2008) 3989-3994
77. Zinzani P.L., Stefoni V., Tani M., et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 27 April (11) (2009) 1781-1787
78. Hutchings M., and Barrington S.F. PET/CT for therapy response assessment in lymphoma. J Nucl Med 50 May (Suppl. 1) (2009) 21S-30S
79. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 February (5) (2007) 579-586
80. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25 February (5) (2007) 571-578
81. Gallamini A., Hutchings M., Rigacci L., et al. Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25 August (24) (2007) 3746-3752
82. Jerusalem G., Beguin Y., Fassotte M.F., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94 July (2) (1999) 429-433
83. Kostakoglu L., Coleman M., Leonard J.P., Kuji I., Zoe H., and Goldsmith S.J. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43 8 (2002) 1018-1027
84. Kasamon Y.L., Jones R.J., and Wahl R.L. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 48 January (Suppl. 1) (2007) 19S-27S
85. Seve P., Billotey C., Broussolle C., Dumontet C., and Mackey J.R. The role of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 109 January (2) (2007) 292-299
86. Fencl P., Belohlavek O., Skopalova M., Jaruskova M., Kantorova I., and Simonova K. Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primary. Eur J Nucl Med Mol Imaging 34 November (11) (2007) 1783-1792
87. Hauth E.A., Antoch G., Stattaus J., et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J Radiol 56 November (2) (2005) 263-268
88. Sironi S., Buda A., Picchio M., et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology 238 January (1) (2006) 272-279
89. Sironi S., Messa C., Mangili G., et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 233 November (2) (2004) 433-440
90. Reinhardt M.J., Joe A.Y., Jaeger U., et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 24 March (7) (2006) 1178-1187
91. Hillner B.E., Liu D., Coleman R.E., et al. The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med 48 November (11) (2007) 1901-1908
92. Hillner B.E., Siegel B.A., Liu D., et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 26 May (13) (2008) 2155-2161
93. Hillner B.E., Siegel B.A., Shields A.F., et al. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer 115 January (2) (2009) 410-418
94. Hillner B.E., Siegel B.A., Shields A.F., et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med 49 December (12) (2008) 1928-1935
95. Townsend D.W., Carney J.P., Yap J.T., and Hall N.C. PET/CT today and tomorrow. J Nucl Med 45 January (Suppl. 1) (2004) 4S-14S